TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2187877

Group type: EXPERIMENTAL
Intervention: Active electromagnetic stimulation units
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dummy control units
Number of subjects: 45
Study: 7008711

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31264903

Group type: EXPERIMENTAL
Intervention: One rescuer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two rescuers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Preexisting training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Learning effect
Number of subjects: 18
Study: 28465557

Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk dairy drink
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 101
Study: 25395354

Group type: EXPERIMENTAL
Intervention: New oak moss
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Classic oak moss
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control subjects (non-allergic)
Number of subjects: 60
Study: 23958945

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 202
Study: 23184900

Group type: EXPERIMENTAL
Intervention: 50,000 IU of oral ergocalciferol weekly for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19914548

Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential treatment arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole followed by Tamoxifen
Number of subjects: 0
Study: 18184078

Group type: EXPERIMENTAL
Intervention: ddI + 1000 mg HU
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ddI + 1500 mg HU
Number of subjects: 69

Group type: COMPARATOR
Intervention: HU monotherapy
Number of subjects: 69
Study: 15700852

Group type: COMPARATOR
Intervention: Gemcitabine (1,000 mg/m2 intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: FLEC (5-fluorouracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused intra-arterially at a 3-week interval 3 times or 5-fluorouracil 400 mg/m2 plus folinic acid 20 mg/m2 for 5 days every 4 weeks for 6 cycles)
Number of subjects: 138
Study: 11240079

Group type: EXPERIMENTAL
Intervention: Behavior-oriented physical therapy (PT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BM rehabilitation (PT+CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (CG)
Number of subjects: 0
Study: 9855165

Group type: EXPERIMENTAL
Intervention: Weight loss and treatment with acetazolamide during a 24‐week period
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Weight loss of 6.2%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 15

Group type: COMPARATOR
Intervention: No weight loss
Number of subjects: 15
Study: 8033506

Group type: EXPERIMENTAL
Intervention: Metoprolol (5 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2728087

Group type: EXPERIMENTAL
Intervention: Bayesian dosing program for phenytoin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group of physicians
Number of subjects: 40
Study: 4157355

Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (2,400,000 U for men; 2,400,000 U daily for 2 days for women)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Spectinomycin hydrochloride (2.0 g for men; 4.0 g for women)
Number of subjects: 334
Study: 31587569

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31156245

Group type: EXPERIMENTAL
Intervention: teberif
Number of subjects: 0

Group type: COMPARATOR
Intervention: rebif
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 27935182

Group type: EXPERIMENTAL
Intervention: Intervention group (training measures for nursing staff and treating physicians)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 195
Study: 25554757

Group type: EXPERIMENTAL
Intervention: Pilot intervention (immunization records obtained, immunization status determined, catch-up doses administered before discharge)
Number of subjects: 356
Study: 22519565

Group type: EXPERIMENTAL
Intervention: Single planning intervention
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: 3 weeks' repeated planning intervention
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: 6 weeks' repeated planning intervention
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: 9 weeks' repeated planning intervention
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 373
Study: 20685179

Group type: COMPARATOR
Intervention: 9 Gy per fraction in two fractions (Control Arm A)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 6.8 Gy per fraction in 3 fractions (Study Arm B)
Number of subjects: 104
Study: 19168553

Group type: EXPERIMENTAL
Intervention: Low dose MDMA (1.0 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High dose MDMA (1.6 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16505498

Group type: EXPERIMENTAL
Intervention: Benfluorex 450 mg/day
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 15807102

Group type: EXPERIMENTAL
Intervention: Interferential electric current stimulation at frequencies deltaf of 10 Hz, 30 Hz, 50 Hz, and 100 Hz.
Number of subjects: 6
Study: 11593350

Group type: EXPERIMENTAL
Intervention: Black tea (5 cups/day for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hot water (5 cups/day for 4 weeks)
Number of subjects: 22
Study: 9844331

Group type: EXPERIMENTAL
Intervention: Occlusion therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 0
Study: 7990479

Group type: EXPERIMENTAL
Intervention: Oral Ftorafur (10 mg/kg daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Oral Ftorafur
Number of subjects: 115
Study: 3058455

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31104111

Group type: EXPERIMENTAL
Intervention: Desensitizing gel applied for 10 min before bleaching with 35% hydrogen peroxide, followed by placebo gel after.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Desensitizing gel applied for 10 min before and after bleaching procedure.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Both groups (desensitizing gel before and before & after)
Number of subjects: 180
Study: 30454075

Group type: EXPERIMENTAL
Intervention: Complex intervention involving changes to the birthing room to encourage an upright position and mobility during labour.
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Control group (standard birthing room environment).
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Complex intervention.
Number of subjects: 3800
Study: 28462761

Group type: EXPERIMENTAL
Intervention: Enhanced cleaning intervention with monitoring and feedback to EVS and infection control staff.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard cleaning (control group).
Number of subjects: 15
Study: 26358534

Group type: EXPERIMENTAL
Intervention: Collective efficacy enhanced intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study: 23360676

Group type: EXPERIMENTAL
Intervention: Special carbohydrate-whey protein cake (3.5:1 ratio)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate cake (control)
Number of subjects: 9
Study: 22013799

Group type: EXPERIMENTAL
Intervention: Xiezhuo Chubi Recipe (XCR)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Benzbromarone Tablet (50 mg, once per day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Blank control group (no treatment)
Number of subjects: 99
Study: 18583433

Group type: EXPERIMENTAL
Intervention: delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 0
Study: 14651539

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS), 7 patients (PG group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group, 13 patients
Number of subjects: 20
Study: 10468028

Group type: EXPERIMENTAL
Intervention: Lactulose 20 mls tds (increasing water content)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Codeine 30 gms qds (decreasing water content)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 16
Study: 8557066

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (80 micrograms kg‐1 bw) subcutaneously twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IGF‐I (100 micrograms kg‐1) in mice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IGF‐I (1 microgram mL‐1) in vitro
Number of subjects: 30
Study: 2172885

Group type: EXPERIMENTAL
Intervention: Megestrol acetate at a dose of 160 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Megestrol acetate at a dose of 480 mg/day
Number of subjects: 40
Study: 582982

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microgram/day p.o.) for 2 days in healthy volunteers
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microgram/day p.o.) for 2 weeks in patients with intractable angina
Number of subjects: 39
Study: 31800496

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment with antibiotics
Number of subjects: 50

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 50
Study: 30698038

Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 784

Group type: COMPARATOR
Intervention: No LBBB
Number of subjects: 784
Study: 28279659

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation protocol (2 sessions a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual treatment (1 session a day)
Number of subjects: 40
Study: 25920649

Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional TKA using an intramedullary guide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional TKA using an extramedullary guide
Number of subjects: 90
Study: 24086732

Group type: EXPERIMENTAL
Intervention: BPSL training
Number of subjects: 94

Group type: COMPARATOR
Intervention: TRAD teaching
Number of subjects: 94
Study: 21851907

Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow mononuclear cells (BMMC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracoronary peripheral blood mononuclear cells (PBMC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 19495945

Group type: EXPERIMENTAL
Intervention: One-time verbal counseling, educational material, reminder aids and follow-up
Number of subjects: 203

Group type: COMPARATOR
Intervention: No organized follow-up or counseling
Number of subjects: 203
Study: 17240120

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg or 20 mg)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 15524059

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10-40 mg daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 and 40 mg daily
Number of subjects: 42
Study: 11878728

Group type: EXPERIMENTAL
Intervention: 2% articaine with 1:200,000 epinephrine
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0.5% bupivacaine and 2% lidocaine
Number of subjects: 82
Study: 9625834

Group type: EXPERIMENTAL
Intervention: Ki-67 index measurement
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ki-67 index in differentiated carcinomas
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ki-67 index in undifferentiated tumors
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High Ki-67 index (55%)
Number of subjects: 130
Study: 7930780

Group type: EXPERIMENTAL
Intervention: Intravenous secretin injection
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Sonographic secretin test
Number of subjects: 159
Study: 30358724

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestogen therapy (EPT) - 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 29873468

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 2
Study: 23640912

Group type: EXPERIMENTAL
Intervention: Internet-based intervention (IT)
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Personal counseling (PC)
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Self-directed control (SD)
Number of subjects: 1685
Study: 23301471

Group type: EXPERIMENTAL
Intervention: Acupoint embedding therapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 218
Study: 20549558

Group type: EXPERIMENTAL
Intervention: Case manager delivered HIV prevention intervention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Experimental case managers
Number of subjects: 25
Study: 19571077

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine infusion at 5 mL/hr
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine infusion
Number of subjects: 158

Group type: COMPARATOR
Intervention: 0.75% ropivacaine infusion and Placebo
Number of subjects: 158
Study: 16624769

Group type: EXPERIMENTAL
Intervention: Vitamin B12 mixed solution inhalation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Gentamycin sulfate mixed solution inhalation
Number of subjects: 122
Study: 15010338

Group type: EXPERIMENTAL
Intervention: Adiponectin levels in cirrhosis
Number of subjects: 20
Study: 11156116

Group type: EXPERIMENTAL
Intervention: Preoperative duplex scanning of the carotid artery, computed tomography of the chest, and intraoperative ultrasonography of the ascending aorta.
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Preoperative parameters analyzed through screening.
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Modifications on the operative procedure for aortic atherosclerosis.
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Overall hospital mortality and morbidity for stroke.
Number of subjects: 308
Study: 9252829

Group type: EXPERIMENTAL
Intervention: Pain killers (specific types not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 8277057

Group type: EXPERIMENTAL
Intervention: Luting agents with resin restorative systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luting agents with ceramic restorative systems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3828603

Group type: EXPERIMENTAL
Intervention: Trained hairdressers
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untrained hairdressers
Number of subjects: 15
Study: 29952648

Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nasotracheal intubation
Number of subjects: 26
Study: 26864920

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 24
Study: 24108307

Group type: EXPERIMENTAL
Intervention: Sumatriptan/naproxen sodium
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 22858285

Group type: EXPERIMENTAL
Intervention: Psoriasis patients
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (patients without psoriasis, n = 134)
Number of subjects: 122
Study: 20572863

Group type: EXPERIMENTAL
Intervention: Changes in self-reported toothbrushing frequency
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Changes in knowledge and attitudes related to oral health
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Associations between changes in toothbrushing frequency and knowledge/attitudes
Number of subjects: 1362
Study: 18721518

Group type: EXPERIMENTAL
Intervention: 1 to 4 drinks/week
Number of subjects: 5153

Group type: EXPERIMENTAL
Intervention: 5 to 7 drinks/week
Number of subjects: 5153

Group type: EXPERIMENTAL
Intervention: >=8 drinks/week
Number of subjects: 5153
Study: 15877983

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 699

Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 699
Study: 12182260

Group type: EXPERIMENTAL
Intervention: Fluticasone and olopatadine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluticasone and fexofenadine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10326791

Group type: EXPERIMENTAL
Intervention: fenretinide (4‐HPR) administered for a mean of 40 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no fenretinide)
Number of subjects: 66
Study: 7549449

Group type: EXPERIMENTAL
Intervention: Surgical trabeculectomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 10
Study: 1952203

Group type: COMPARATOR
Intervention: Breathing room air (or maintenance inspired oxygen fraction)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Breathing 100% O2
Number of subjects: 23
Study: 7005681

Group type: EXPERIMENTAL
Intervention: Chlorambucil supplemented by phlebotomy
Number of subjects: 431

Group type: COMPARATOR
Intervention: Radioactive phosphorus supplemented by phlebotomy
Number of subjects: 431

Group type: COMPARATOR
Intervention: Phlebotomy alone
Number of subjects: 431
Study: 31901794

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 150
Study: 31651042

Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian Randomization (MR) using two-stage least squares (2SLS) procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bias-corrected estimator for the causal effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numeric simulations
Number of subjects: 0
Study: 28583814

Group type: EXPERIMENTAL
Intervention: Open Roux-en-Y gastric bypass (RYGB)
Number of subjects: 166601

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 166601

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 166601

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 166601

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion/duodenal switch (BPD/DS)
Number of subjects: 166601
Study: 26337944

Group type: EXPERIMENTAL
Intervention: High-dose ranibizumab (1.0/0.1 ml or 2.0 mg/0.05 ml; n=15)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-dose ranibizumab (0.5 mg/0.05 ml; n=5)
Number of subjects: 20
Study: 23867026

Group type: EXPERIMENTAL
Intervention: 2009 H1N1 prevention and control messages
Number of subjects: 1992

Group type: COMPARATOR
Intervention: Tobacco-cessation messages
Number of subjects: 1992
Study: 21641183

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 50
Study: 19176729

Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 221

Group type: COMPARATOR
Intervention: No maternal depressive symptoms (control group)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Caregiving practices
Number of subjects: 221
Study: 17540216

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter/defibrillator (ICD)
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 2521
Study: 15161453

Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) training
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 11165993

Group type: EXPERIMENTAL
Intervention: Misoprostol in combination with NSAID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nabumetone
Number of subjects: 0
Study: 9432097

Group type: EXPERIMENTAL
Intervention: Terbutaline (3 mg from MDI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8501471

Group type: EXPERIMENTAL
Intervention: First-class stamp
Number of subjects: 380

Group type: COMPARATOR
Intervention: Business reply mail
Number of subjects: 380
Study: 3690029

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 11
Study: 31383515

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) through a Turbosonic vibratory machine for 10 minutes
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Localized perilaryngeal vibration (LPV) with a Novofan vibrator for 10 minutes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (sham hand-held vibratory device)
Number of subjects: 44
Study: 30834870

Group type: EXPERIMENTAL
Intervention: Contec CMS50D Fingertip Pulse Oximeter
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nihon Kohden Life Scope MU-631 RK conventional bedside monitor
Number of subjects: 220
Study: 28364943

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Amygdala lesions
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 78
Study: 26433802

Group type: EXPERIMENTAL
Intervention: Acupuncture at SP-6 and LI-4 points
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham acupuncture at SP-6 and LI-4 points
Number of subjects: 63